An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age

Trial Profile

An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age

Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 Jul 2017

At a glance

  • Drugs GSK 2654909A (Primary) ; GSK 2654911A (Primary)
  • Indications Influenza A virus H9N2 subtype
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 15 Jul 2017 Results published in the Vaccine Journal.
    • 10 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Sep 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top